Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung CancerJustin F. Gainor, Lecia V. Sequist, Beow Y. Yeap et al.|Clinical Cancer Research|2021Cited by 137
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Liron Bar‐Peled, Sarah Reeves et al.|Cell|2024Cited by 94
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2017Cited by 10
DrugMap: A quantitative pan-cancer analysis of cysteine ligandabilityMariko Takahashi, Sarah Reeves, Harrison B. Chong et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 8
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Tomoko Betsuyaku, Katsuhiko Naoki et al.|Cancer Chemotherapy and Pharmacology|2015Cited by 7